Welcome to our dedicated page for BIORA THERAPEUTICS news (Ticker: BIOR), a resource for investors and traders seeking the latest updates and insights on BIORA THERAPEUTICS stock.
Biora Therapeutics (formerly trading under the symbol BIOR) has generated frequent news coverage around its development of smart pill-based therapeutic delivery platforms and its corporate restructuring. Company releases describe Biora as a clinical-stage biotech focused on two main platforms: NaviCap, for colon-targeted treatment of inflammatory bowel disease, and BioJet, a swallowable autoinjector platform for oral delivery of large molecules designed to replace injection with needle-free, oral administration.
News items detail progress on the BioJet™ Oral Delivery Platform, including development of a smaller, 00-size device with increased payload capacity compared with a larger 000-size capsule. Biora reports that the 00-size BioJet device is designed to deliver standard liquid drug formulations with a capacity greater than 300 microliters and to enable doses greater than 50 milligrams. Releases also describe in vivo studies, work with collaborator molecules, and presentations at industry meetings such as the Partnership Opportunities in Drug Delivery meeting and the Peptide Therapeutics Symposium.
Another major theme in Biora’s news flow is the NaviCap™ platform and its application to inflammatory bowel disease. The company has announced Phase 1 clinical trial data for BT-600, a NaviCap-based program, presented at a leading gastroenterology conference and recognized with a Presidential Poster Award, with the results suggesting the potential for larger clinical trials in ulcerative colitis patients.
In addition to R&D updates, Biora’s news includes financing transactions, Nasdaq listing developments, and a chapter 11 filing in the District of Delaware as part of a court-supervised sale process. Subsequent news reports the completion of this restructuring, with Biora emerging as a privately held company and its existing common shares cancelled pursuant to a Plan of Reorganization. Readers following BIOR-related news can review this sequence of scientific, clinical, financial, and restructuring announcements to understand the company’s evolution and platform development.
Biora Therapeutics presented new clinical data on its NaviCap™ platform at the Digestive Disease Week 2024 conference. The studies demonstrated the device's ability to deliver therapeutics directly to the colon in varied gastrointestinal conditions and eating schedules. Conducted on 47 participants, including those with active ulcerative colitis (UC), the trials showed the device was well-tolerated, with no serious adverse events reported. The NaviCap uses GItrac™ technology to autonomously target locations in the GI tract, ensuring effective delivery. The findings suggest potential improvements in treating inflammatory bowel diseases.
Biora Therapeutics reported their Q1 2024 financial results and provided a corporate update. They have completed dosing all patients in the clinical trial for BT-600, with results expected in late Q2 2024. Interim results showed consistent drug delivery to the colon. They will present NaviCap™ platform data at the DDW conference on May 19. Partnering progress for the BioJet oral delivery platform is ongoing. Financially, Biora raised $31 million in new capital and reported a net loss of $4.2 million for Q1 2024, an improvement from a $17.4 million net loss in Q1 2023.
Biora Therapeutics, Inc. (Nasdaq: BIOR) will report financial results and provide a corporate update for Q1 2024 on May 15, 2024. The company focuses on therapeutic delivery and will host a webcast and conference call after the market close. Investors can access the call online for 60 days.
Biora Therapeutics, Inc. (Nasdaq: BIOR) will present clinical data on the device function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024. The presentation will include results of human device function studies in healthy volunteers and patients with UC. The abstract will be presented by Shaoying Nikki Lee, PhD, Director of Clinical and Translational Science at Biora Therapeutics, Inc.
Biora Therapeutics, Inc. (Nasdaq: BIOR) announces the completion of dosing for multiple-ascending dose cohorts in the clinical trial of BT-600 for potential treatment of ulcerative colitis. Final results expected in late Q2 2024. The trial evaluated daily doses of BT-600 for seven days at 5 mg and 10 mg tofacitinib or placebo in healthy adult participants. Positive interim results from the single-ascending dose portion have been previously shared.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.